<DOC>
	<DOCNO>NCT01322815</DOCNO>
	<brief_summary>The purpose study test safety GI-4000 see effect ( good bad ) cancer time . This study also do measure immune response GI-4000 . Study drug give addition standard care standard therapy give patient type cancer ( colon ) .</brief_summary>
	<brief_title>A Pilot Trial GI-4000 Plus Bevacizumab Either FOLFOX FOLFIRI</brief_title>
	<detailed_description>Subject visit occur 1-4 week prior initiation GI-4000 , - In newly diagnose ( Group A ) patient , every FOLFOX/FOLFIRI plus bevacizumab visit , bevacizumab GI-4000 dosing visit , GI-4000 dose visit quarterly completion therapy - In patient stable disease complete first line therapy oxaliplatin irinotecan plus fluoropyrimidine bevacizumab contain regimen ( Group B ) , every bevacizumab GI-4000 dosing visit , GI-4000 dose visit quarterly completion therapy Group A patient ( N=26 ) enrol study prior initiation first line therapy bevacizumab plus either FOLFOX ( N=13 ) FOLFIRI ( N=13 ) - Subjects receive 1 40 yeast unit ( YU ) dose GI-4000 prior initiation FOLFOX FOLFIRI plus bevacizumab , intercycle dose GI-4000 give 7 day cycle first line therapy give ( 8 cycle ) - After completion first line therapy , subject enter maintenance phase bevacizumab GI-4000 give concurrently every 2 week long therapy tolerate progression - If subject discontinues bevacizumab therapy due intolerance , subject continue GI-4000 every 2 week progression , intolerance withdrawal study Group B patient ( N=26 ) stable disease complete first line therapy oxaliplatin irinotecan plus fluoropyrimidine bevacizumab contain regimen ) enter trial prior receive therapy bevacizumab - Subjects receive 40 yeast unit ( YU ) GI-4000 concurrently bevacizumab dose long therapy tolerate progression - If subject discontinues bevacizumab therapy due intolerance , subject continue GI-4000 every 2 week progression , intolerance withdrawal study</detailed_description>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis metastatic colorectal cancer Ras mutation Measurable evaluable disease No prior therapy fore metastatic disease except group A : &gt; 6 month since completion adjuvant therapy Group B : patient enroll complete bevacizumab plus FOLFOX FOLFIRI Anticipated survival least 6 month Ambulatory Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Ability maintain weight Normal organ marrow function Women childbearing potential men must agree avoid pregnancy father child duration study participation 6 month final schedule study visit . Ability understand willingness sign write informed consent document Prior chemotherapy list inclusion criterion Receiving investigational agent Known brain metastasis , uncontrolled seizure disorder , encephalitis , multiple sclerosis History know hypersensitivity S. cerevisiae , bevacizumab component FOLFOX FOLFIRI Concurrent chronic therapy corticosteroid immunosuppressive drug Uncontrolled hypertension , unstable angina , congestive heart failure , peripheral vascular disease , serious cardiac arrythmias require medication History heart attack stroke within 6 month enrollment History intraabdominal abscess , abdominal fistula , gastrointestinal perforation , active peptic ulcer disease Bleeding disorder coagulopathy Serious nonhealing wound , ulcer bone fracture Major surgical procedure , open biopsy , traumatic injury within 4 week prior enrollment anticipation need surgery study Known active infection HIV , hepatitis B C History splenectomy History Crohn 's disease ulcerative colitis History organ transplantation Evidence immunodeficiency immune suppression Any Autoimmune disease Active infection Concurrent malignancy Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>colon cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>vaccine</keyword>
</DOC>